The DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.
Chemically Induced Degradation of Sirtuin 2 (Sirt2) by a Proteolysis Targeting Chimera (PROTAC) Based on Sirtuin Rearranging Ligands (SirReals)
Open accessAbstract
Here we report the development of a proteolysis targeting chimera (PROTAC) based on the combination of the unique features of the sirtuin rearranging ligands (SirReals) as highly potent and isotype-selective Sirt2 inhibitors with thalidomide, a bona fide cereblon ligand. For the first time, we report the formation of a PROTAC by Cu(I)-catalyzed cycloaddition of a thalidomide-derived azide to an alkynylated inhibitor. This thalidomide-derived azide as well as the highly versatile linking strategy can be readily adapted to alkynylated ligands of other targets. In HeLa cells, our SirReal-based PROTAC induced isotype-selective Sirt2 degradation that results in the hyperacetylation of the microtubule network coupled with enhanced process elongation. Thus, our SirReal-based PROTAC is the first example of a probe that is able to chemically induce the degradation of an epigenetic eraser protein.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bradford, M. M. (1976) · Analytical Biochemistry · doi:10.1016/0003-2697(76)90527-3 · Cited by 255,302
Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4
LAEMMLI, U. K. (1970) · Nature · doi:10.1038/227680a0 · Cited by 249,961
Development and testing of a general amber force field
Wang, J., Wolf, R. M., Caldwell, J. W., Kollman, P. A., & Case, D. A. (2004) · Journal of Computational Chemistry · doi:10.1002/jcc.20035 · Cited by 19,506
Baell, J. B., & Holloway, G. A. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901137j · Cited by 3,944
The growing impact of click chemistry on drug discovery
Kolb, H. C., & Sharpless, K. B. (2003) · Drug Discovery Today · doi:10.1016/s1359-6446(03)02933-7 · Cited by 3,716
Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase
Imai, S.-I., Armstrong, C. M., Kaeberlein, M., & Guarente, L. (2000) · Nature · doi:10.1038/35001622 · Cited by 3,510
Histone deacetylases (HDACs): characterization of the classical HDAC family
RUIJTER, A. J. M. D., GENNIP, A. H. V., CARON, H. N., KEMP, S., & KUILENBURG, A. B. P. V. (2003) · Biochemical Journal · doi:10.1042/bj20021321 · Cited by 3,114
Improved protein–ligand docking using GOLD
Verdonk, M. L., Cole, J. C., Hartshorn, M. J., Murray, C. W., & Taylor, R. D. (2003) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.10465 · Cited by 3,067
The HADDOCK2.2 Web Server: User-Friendly Integrative Modeling of Biomolecular Complexes
van Zundert, G. C. P., Rodrigues, J. P. G. L. M., Trellet, M., Schmitz, C., Kastritis, P. L., Karaca, E., Melquiond, A. S. J., van Dijk, M., de Vries, S. J., & Bonvin, A. M. J. J. (2016) · Journal of Molecular Biology · doi:10.1016/j.jmb.2015.09.014 · Cited by 2,785
Modulation of NF‐κB‐dependent transcription and cell survival by the SIRT1 deacetylase
Yeung, F., Hoberg, J. E., Ramsey, C. S., Keller, M. D., Jones, D. R., Frye, R. A., & Mayo, M. W. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600244 · Cited by 2,750
hSIR2SIRT1 Functions as an NAD-Dependent p53 Deacetylase
Vaziri, H., Dessain, S. K., Eaton, E. N., Imai, S.-I., Frye, R. A., Pandita, T. K., Guarente, L., & Weinberg, R. A. (2001) · Cell · doi:10.1016/s0092-8674(01)00527-x · Cited by 2,659
Phthalimide conjugation as a strategy for in vivo target protein degradation
Winter, G. E., Buckley, D. L., Paulk, J., Roberts, J. M., Souza, A., Dhe-Paganon, S., & Bradner, J. E. (2015) · Science · doi:10.1126/science.aab1433 · Cited by 1,760
The Human Sir2 Ortholog, SIRT2, Is an NAD+-Dependent Tubulin Deacetylase
North, B. J., Marshall, B. L., Borra, M. T., Denu, J. M., & Verdin, E. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00038-8 · Cited by 1,536
Polytriazoles as Copper(I)-Stabilizing Ligands in Catalysis
Chan, T. R., Hilgraf, R., Sharpless, K. B., & Fokin, V. V. (2004) · Organic Letters · doi:10.1021/ol0493094 · Cited by 1,531
Sirt5 Is a NAD-Dependent Protein Lysine Demalonylase and Desuccinylase
Du, J., Zhou, Y., Su, X., Yu, J. J., Khan, S., Jiang, H., Kim, J., Woo, J., Kim, J. H., Choi, B. H., et al. (2011) · Science · doi:10.1126/science.1207861 · Cited by 1,429
Catalytic in vivo protein knockdown by small-molecule PROTACs
Bondeson, D. P., Mares, A., Smith, I. E. D., Ko, E., Campos, S., Miah, A. H., Mulholland, K. E., Routly, N., Buckley, D. L., Gustafson, J. L., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1858 · Cited by 1,356
Mammalian sirtuins—emerging roles in physiology, aging, and calorie restriction
Haigis, M. C., & Guarente, L. P. (2006) · Genes & Development · doi:10.1101/gad.1467506 · Cited by 1,295
Structure of the DDB1–CRBN E3 ubiquitin ligase in complex with thalidomide
Fischer, E. S., Böhm, K., Lydeard, J. R., Yang, H., Stadler, M. B., Cavadini, S., Nagel, J., Serluca, F., Acker, V., Lingaraju, G. M., et al. (2014) · Nature · doi:10.1038/nature13527 · Cited by 1,141
Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4
Lu, J., Qian, Y., Altieri, M., Dong, H., Wang, J., Raina, K., Hines, J., Winkler, J. D., Crew, A. P., Coleman, K., et al. (2015) · Chemistry & Biology · doi:10.1016/j.chembiol.2015.05.009 · Cited by 1,140
Sirtuin 2 Inhibitors Rescue α-Synuclein-Mediated Toxicity in Models of Parkinson's Disease
Outeiro, T. F., Kontopoulos, E., Altmann, S. M., Kufareva, I., Strathearn, K. E., Amore, A. M., Volk, C. B., Maxwell, M. M., Rochet, J.-C., McLean, P. J., et al. (2007) · Science · doi:10.1126/science.1143780 · Cited by 1,062
Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4
Zengerle, M., Chan, K.-H., & Ciulli, A. (2015) · ACS Chemical Biology · doi:10.1021/acschembio.5b00216 · Cited by 1,056
Lysine glutarylation is a protein posttranslational modification regulated by SIRT5
Tan, M., Peng, C., Anderson, K. A., Chhoy, P., Xie, Z., Dai, L., Park, J., Chen, Y., Huang, H., Zhang, Y., et al. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.03.014 · Cited by 844
SIRT6 regulates TNF-α secretion through hydrolysis of long-chain fatty acyl lysine
Jiang, H., Khan, S., Wang, Y., Charron, G., He, B., Sebastian, C., Du, J., Kim, R., Ge, E., Mostoslavsky, R., et al. (2013) · Nature · doi:10.1038/nature12038 · Cited by 697
Small‐Molecule PROTACS: New Approaches to Protein Degradation
Toure, M., & Crews, C. M. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201507978 · Cited by 674
Sirtuin regulation of mitochondria: energy production, apoptosis, and signaling
Verdin, E., Hirschey, M. D., Finley, L. W. S., & Haigis, M. C. (2010) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2010.07.003 · Cited by 661
Feldman, J. L., Baeza, J., & Denu, J. M. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.c113.511261 · Cited by 637
Schneekloth, A. R., Pucheault, M., Tae, H. S., & Crews, C. M. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.07.114 · Cited by 635
Modular PROTAC design for the degradation of oncogenic BCR-ABL
Lai, A. C., Toure, M., Hellerschmied, D., Salami, J., Jaime‐Figueroa, S., Ko, E., Hines, J., & Crews, C. M. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201507634 · Cited by 618
SIRT2 Maintains Genome Integrity and Suppresses Tumorigenesis through Regulating APC/C Activity
Kim, H.-S., Vassilopoulos, A., Wang, R.-H., Lahusen, T., Xiao, Z., Xu, X., Li, C., Veenstra, T. D., Li, B., Yu, H., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.09.004 · Cited by 537
SIRT Inhibitors Induce Cell Death and p53 Acetylation through Targeting Both SIRT1 and SIRT2
Peck, B., Chen, C.-Y., Ho, K.-K., Di Fruscia, P., Myatt, S. S., Coombes, R. C., Fuchter, M. J., Hsiao, C.-D., & Lam, E. W.-F. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0971 · Cited by 433
Development of Protacs to Target Cancer-promoting Proteins for Ubiquitination and Degradation
Sakamoto, K. M., Kim, K. B., Verma, R., Ransick, A., Stein, B., Crews, C. M., & Deshaies, R. J. (2003) · Molecular & Cellular Proteomics · doi:10.1074/mcp.t300009-mcp200 · Cited by 425
SIRT1 and SIRT2: emerging targets in neurodegeneration
Donmez, G., & Outeiro, T. F. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201302451 · Cited by 411
Liu, T. F., Vachharajani, V. T., Yoza, B. K., & McCall, C. E. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.362343 · Cited by 340
SIRT2 inhibition achieves neuroprotection by decreasing sterol biosynthesis
Luthi-Carter, R., Taylor, D. M., Pallos, J., Lambert, E., Amore, A., Parker, A., Moffitt, H., Smith, D. L., Runne, H., Gokce, O., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1002924107 · Cited by 336
Bao, X., Wang, Y., Li, X., Li, X.-M., Liu, Z., Yang, T., Wong, C. F., Zhang, J., Hao, Q., & Li, X. D. (2014) · eLife · doi:10.7554/elife.02999 · Cited by 324
Studies in Classification Data Analysis and knowledge Organization
Vichi, M. (2008) · IRIS Research product catalog (Sapienza University of Rome) · Cited by 302
Selective Sirt2 inhibition by ligand-induced rearrangement of the active site
Rumpf, T., Schiedel, M., Karaman, B., Roessler, C., North, B. J., Lehotzky, A., Oláh, J., Ladwein, K. I., Schmidtkunz, K., Gajer, M., et al. (2015) · Nature Communications · doi:10.1038/ncomms7263 · Cited by 297
Self-citationA Role for SIRT2-Dependent Histone H3K18 Deacetylation in Bacterial Infection
Eskandarian, H. A., Impens, F., Nahori, M.-A., Soubigou, G., Coppée, J.-Y., Cossart, P., & Hamon, M. A. (2013) · Science · doi:10.1126/science.1238858 · Cited by 267
Salermide, a Sirtuin inhibitor with a strong cancer-specific proapoptotic effect
Lara, E., Mai, A., Calvanese, V, Altucci, L., Lopez-Nieva, P., Martinez-Chantar, M. L., Varela-Rey, M., Rotili, D., Nebbioso, A., Ropero, S., et al. (2009) · Oncogene · doi:10.1038/onc.2008.436 · Cited by 259
SIRT2 induces the checkpoint kinase BubR1 to increase lifespan
North, B. J., Rosenberg, M. A., Jeganathan, K. B., Hafner, A. V., Michan, S., Dai, J., Baker, D. J., Cen, Y., Wu, L. E., Sauve, A. A., et al. (2014) · The EMBO Journal · doi:10.15252/embj.201386907 · Cited by 238
The Sirtuin 2 Inhibitor AK-7 Is Neuroprotective in Huntington’s Disease Mouse Models
Chopra, V., Quinti, L., Kim, J., Vollor, L., Narayanan, K. L., Edgerly, C., Cipicchio, P. M., Lauver, M. A., Choi, S. H., Silverman, R. B., et al. (2012) · Cell Reports · doi:10.1016/j.celrep.2012.11.001 · Cited by 212
Transcriptional targets of sirtuins in the coordination of mammalian physiology
Feige, J. N., & Auwerx, J. (2008) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2008.03.012 · Cited by 206
Pais, T. F., Szegő, É. M., Marques, O., Miller‐Fleming, L., Antas, P., Guerreiro, P., de Oliveira, R. M., Kasapoglu, B., & Outeiro, T. F. (2013) · The EMBO Journal · doi:10.1038/emboj.2013.200 · Cited by 175
Beirowski, B., Gustin, J., Armour, S. M., Yamamoto, H., Viader, A., North, B. J., Michán, S., Baloh, R. H., Golden, J. P., Schmidt, R. E., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1104969108 · Cited by 174
Neugebauer, R. C., Uchiechowska, U., Meier, R., Hruby, H., Valkov, V., Verdin, E., Sippl, W., & Jung, M. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm700972e · Cited by 166
Self-citationCompartmentalization of superoxide dismutase 1 (SOD1G93A) aggregates determines their toxicity
Weisberg, S. J., Lyakhovetsky, R., Werdiger, A.-C., Gitler, A. D., Soen, Y., & Kaganovich, D. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1205829109 · Cited by 149
Hoffmann, G., Breitenbücher, F., Schüler, M., & Ehrenhofer‐Murray, A. E. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.487736 · Cited by 144
HDAC6 and SIRT2 Regulate the Acetylation State and Oncogenic Activity of Mutant K-RAS
Yang, M. H., Laurent, G., Bause, A. S., Spang, R., German, N. J., Haigis, M. C., & Haigis, K. M. (2013) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0040-t · Cited by 144
SIRT2 as a Therapeutic Target for Age-Related Disorders
de Oliveira, R. M., Sarkander, J., Kazantsev, A. G., & Outeiro, T. F. (2012) · Frontiers in Pharmacology · doi:10.3389/fphar.2012.00082 · Cited by 143
The Current State of NAD+‐Dependent Histone Deacetylases (Sirtuins) as Novel Therapeutic Targets
Schiedel, M., Robaa, D., Rumpf, T., Sippl, W., & Jung, M. (2017) · Medicinal Research Reviews · doi:10.1002/med.21436 · Cited by 137
Self-citationOkuhira, K., Demizu, Y., Hattori, T., Ohoka, N., Shibata, N., Nishimaki‐Mogami, T., Okuda, H., Kurihara, M., & Naito, M. (2013) · Cancer Science · doi:10.1111/cas.12272 · Cited by 133
Taylor, D. M., Balabadra, U., Xiang, Z., Woodman, B., Meade, S., Amore, A. M., Maxwell, M. M., Reeves, S. A., Bates, G. P., Luthi‐Carter, R., et al. (2011) · ACS Chemical Biology · doi:10.1021/cb100376q · Cited by 132
Saubern, S., Guha, R., & Baell, J. B. (2011) · Molecular Informatics · doi:10.1002/minf.201100076 · Cited by 131
Bobrowska, A., Dönmez, G., Weiss, A., Guarente, L., & Bates, G. P. (2012) · PLoS ONE · doi:10.1371/journal.pone.0034805 · Cited by 131
Design, Synthesis, and Biological Activity of a Novel Series of Human Sirtuin-2-Selective Inhibitors
Suzuki, T., Khan, M. N. A., Sawada, H., Imai, E., Itoh, Y., Yamatsuta, K., Tokuda, N., Takeuchi, J., Seko, T., Nakagawa, H., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm3002108 · Cited by 130
Seifert, T., Malo, M., Kokkola, T., Engen, K., Fridén‐Saxin, M., Wallén, E. A. A., Lahtela-Kakkonen, M. K., Jarho, E. M., & Luthman, K. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500930h · Cited by 125
In vitro assays for the determination of histone deacetylase activity
Heltweg, B., Trapp, J., & Jung, M. (2005) · Methods · doi:10.1016/j.ymeth.2005.03.003 · Cited by 116
Self-citationSIRT7 Is an RNA-Activated Protein Lysine Deacylase
Tong, Z., Wang, M., Wang, Y., Kim, D. D., Grenier, J. K., Cao, J., Sadhukhan, S., Hao, Q., & Lin, H. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.6b00954 · Cited by 107
Sirt2 interacts with 14-3-3 β/γ and down-regulates the activity of p53
Jin, Y.-H., Kim, Y.-J., Kim, D., Baek, K., Kang, B. Y., Yeo, C., & Lee, K.-Y. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.01.114 · Cited by 103
Aminothiazoles as Potent and Selective Sirt2 Inhibitors: A Structure–Activity Relationship Study
Schiedel, M., Rumpf, T., Karaman, B., Lehotzky, A., Oláh, J., Gerhardt, S., Ovádi, J., Sippl, W., Einsle, O., & Jung, M. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01517 · Cited by 102
Self-citationNAD+-dependent histone deacetylases (sirtuins) as novel therapeutic targets
Schemies, J., Uciechowska, U., Sippl, W., & Jung, M. (2009) · Medicinal Research Reviews · doi:10.1002/med.20178 · Cited by 98
Self-citationHuman Histone Deacetylase SIRT2 Interacts with the Homeobox Transcription Factor HOXA10
Bae, N. S., Swanson, M. J., Vassilev, A., & Howard, B. H. (2004) · The Journal of Biochemistry · doi:10.1093/jb/mvh084 · Cited by 93
Discovery of Potent and Selective Sirtuin 2 (SIRT2) Inhibitors Using a Fragment-Based Approach
Cui, H., Kamal, Z., Ai, T., Xü, Y., More, S. S., Wilson, D. J., & Chen, L. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500777s · Cited by 86
Park, S., Zhu, Y., Özden, Ö., Kim, H. S., Jiang, H., Deng, C., Gius, D. R., & Vassilopoulos, A. (2012) · PubMed · Cited by 85
Structure‐Based Development of an Affinity Probe for Sirtuin 2
Schiedel, M., Rumpf, T., Karaman, B., Lehotzky, A., Gerhardt, S., Ovádi, J., Sippl, W., Einsle, O., & Jung, M. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201509843 · Cited by 79
Self-citationSIRT7 Is Activated by DNA and Deacetylates Histone H3 in the Chromatin Context
Tong, Z., Wang, Y., Zhang, X., Kim, D. D., Sadhukhan, S., Hao, Q., & Lin, H. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.5b01084 · Cited by 75
Fruscia, P. D., Zacharioudakis, E., Liu, C., Moniot, S., Laohasinnarong, S., Khongkow, M., Harrison, I. F., Koltsida, K., Reynolds, C. R., Schmidtkunz, K., et al. (2014) · ChemMedChem · doi:10.1002/cmdc.201402431 · Cited by 73
Self-citationCunningham, C. W., Mukhopadhyay, A., Lushington, G. H., Blagg, B. S. J., Prisinzano, T. E., & Krise, J. P. (2010) · Molecular Pharmaceutics · doi:10.1021/mp100089k · Cited by 64
Selective Inhibition of SIRT2 Improves Outcomes in a Lethal Septic Model
Zhao, T., Alam, H. B., Liu, B., Bronson, R. T., Nikolian, V. C., Wu, E., Chong, W., & Li, Y. (2015) · Current Molecular Medicine · doi:10.2174/156652401507150903185852 · Cited by 53
Practical synthesis of a phthalimide-based Cereblon ligand to enable PROTAC development
Lohbeck, J., & Miller, A. K. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.09.048 · Cited by 42
Cited by
PROteolysis TArgeting Chimeras (PROTACs) — Past, present and future
Pettersson, M., & Crews, C. M. (2019) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2019.01.002 · Cited by 800
The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study
Burslem, G. M., Smith, B. E., Lai, A. C., Jaime-Figueroa, S., McQuaid, D. C., Bondeson, D. P., Toure, M., Dong, H., Qian, Y., Wang, J., et al. (2018) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.09.009 · Cited by 686
A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo
Bai, L., Zhou, H., Xu, R., Zhao, Y., Chinnaswamy, K., McEachern, D., Chen, J., Yang, C.-Y., Liu, Z., Wang, M., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.10.002 · Cited by 652
PROTACs: great opportunities for academia and industry
Sun, X., Gao, H., Yang, Y., He, M., Wu, Y., Song, Y., Tong, Y., & Rao, Y. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0101-6 · Cited by 613
Targeted protein degradation: elements of PROTAC design
Paiva, S.-L., & Crews, C. M. (2019) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2019.02.022 · Cited by 576
Metadata
- Authors
- Schiedel, M., Herp, D., Hammelmann, S., Swyter, S., Lehotzky, A., Robaa, D., Oláh, J., Ovádi, J., Sippl, W., & Jung, M.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2017-04-17
- Volume
- 61
- Issue
- 2
- Pages
- 482-491
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2604930678
- Cited by
- 263
- References
- 70
- FWCI
- 10.97
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.